Vical to stop developing melanoma therapy after trial failure
Aug 12 (Reuters) - Vical Inc said it will stop developing its experimental cancer therapy Allovectin after a late-stage trial failed to show that the treatment was significantly better than chemotherapy.
The company said it now planned to focus on its infectious disease vaccine programs.
The trial tested Allovectin in patients with metastatic melanoma.
- Target says data from 40 million cards stolen in November-December
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Facebook, Zuckerberg, banks must face IPO lawsuit: judge
- As Modi storms into India's election, a quiet alternative emerges
- U.S. prosecutor defends treatment of Indian diplomat |